Medivir AB Stock price

Equities

MVIR B

SE0020181014

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 07:59:51 2024-03-28 am EDT 5-day change 1st Jan Change
2.748 SEK -0.90% Intraday chart for Medivir AB -2.78% -3.60%
Sales 2023 9M 842K Sales 2024 * 26.75M 2.5M Capitalization 311M 29.08M
Net income 2023 -89M -8.33M Net income 2024 * -96M -8.99M EV / Sales 2023 -1.16 x
Net cash position 2023 170M 15.88M Net cash position 2024 * 94.7M 8.86M EV / Sales 2024 * 8.07 x
P/E ratio 2023
-1.93 x
P/E ratio 2024 *
-3.06 x
Employees 10
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.19%
More Fundamentals * Assessed data
Dynamic Chart
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024. CI
Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit CI
Transcript : Medivir AB, Q4 2023 Earnings Call, Feb 15, 2024
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Medivir AB - Special Call
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress CI
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer CI
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers CI
Medivir, Lonza Sign Manufacturing Deal for Fostrox MT
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval CI
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization MT
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC CI
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA CI
Transcript : Medivir AB - Special Call
More news
1 day-2.40%
1 week-2.74%
Current month-11.61%
1 month-14.91%
3 months-3.22%
6 months-61.26%
Current year-3.56%
More quotes
1 week
2.50
Extreme 2.4995
2.94
1 month
2.50
Extreme 2.4995
3.22
Current year
2.50
Extreme 2.4995
3.64
1 year
2.50
Extreme 2.4995
8.58
3 years
2.50
Extreme 2.4995
11.84
5 years
2.50
Extreme 2.4995
28.05
10 years
2.50
Extreme 2.4995
151.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 22-01-23
Director of Finance/CFO 50 19-08-11
Chairman 74 18-05-02
Members of the board TitleAgeSince
Chairman 74 18-05-02
Director/Board Member 68 18-05-02
Director/Board Member 45 20-05-25
More insiders
Date Price Change Volume
24-03-28 2.748 -0.90% 843 740
24-03-27 2.772 -2.33% 144,328
24-03-26 2.838 +3.37% 507,195
24-03-25 2.746 +0.59% 87,131
24-03-22 2.73 -3.40% 106,199

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:26 am EDT

More quotes
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.772 SEK
Average target price
20.55 SEK
Spread / Average Target
+641.36%
Consensus
  1. Stock
  2. Equities
  3. Stock Medivir AB - Nasdaq Stockholm